Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation.
Alessio CortelliniBiagio RicciutiMarcello TiseoEmilio BriaGiuseppe L BannaJoachim Gjv AertsFausto BarbieriRaffaele GiustiDiego L CortinovisMaria R MigliorinoAnnamaria CatinoFrancesco PassigliaMariangela TorniaiAlessandro MorabitoCarlo GenovaFrancesca MazzoniVincenzo Di NoiaDiego SignorelliAlain GelibterMario Alberto OcchipintiFrancesca RastelliRita ChiariDanilo RoccoAlessandro InnoMichele De TursiPietro Di MarinoGiovanni MansuetoFederica ZorattoFrancesco GrossiMarco FilettiPamela PizzutiloMarco RussanoFabrizio CitarellaLuca CantiniGiada TargatoOlga NigroMiriam G FerraraSebastiano ButiSimona ScodesLorenza LandiGiorgia GuaitoliLuigi Della GravaraFabrizio TabbòSerena RicciardiAlessandro De TomaAlex FriedlaenderFausto PetrelliAlfredo AddeoGiampiero PorzioCorrado FicorellaPublished in: Journal for immunotherapy of cancer (2021)
Baseline obesity is associated to significantly improved ORR, PFS and OS in metastatic NSCLC patients with a PD-L1 expression of ≥50%, receiving first line pembrolizumab, but not among patients treated with chemotherapy. BMI variation is also significantly related to clinical outcomes.